EGFR and non-small cell lung carcinoma: Patients with advanced NSCLC and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) mutation were recruited in a study that investigated the safety and efficacy of the combined therapy, ginsenoside Rg3 and EGFR-TKI.